Teng Jin1, Zhenwei Yao1, Jianxun Qu2, and Yong Zhang3
1Huashan Hospital, Fudan University, Shanghai, China, 2GE Healthcare, Shanghai, China, 3GE Healthcare,Shanghai,China, Shanghai, China
Synopsis
The treatment for brain
metastasis are mainly depended on the number, size and location of lesions, to
evaluate the number of brain metastatic lesions sensitively with contrast enhanced
series is more important for patient treatment. The aim of this study was to
assess the efficiency of half-dose contrast enhanced T2FLAIR used in the
detection of intracranial metastases in comparison to full-dose enhanced
T1-weighted imaging.
Background and objective
Background: Brain metastasis treatment mainly depends on the number, size,
and location of lesions. It is important for treatment to sensitively evaluate the number of brain metastases using a contrast
enhanced (CE) series.
Objective: To assess the detection rate and image quality of ½-dose CE T2-fluid-attenuated
inversion recovery (FLAIR) in intracranial metastases, compared with CE-T1-weighted
imaging (T1WI).
Materials and Methods
Materials and Methods:Thirty-three patients with known cancers and
brain metastasis underwent pre- and post-contrast sequences including: i) ½-dose
CE-T2-FLAIR, ii) ½-dose CE-T1WI, and iii) full-dose CE-3D-BRAVO sequence scan.
The optimum scanning time for ½-dose CE-T2-FLAIR was analyzed, and we compared contrast
ratio (CR) and the number of parenchymal metastases on three sequences above.Results:
Results: One hundred and forty-one ½-dose CE-T2-FLAIR, 88 ½-dose
CE-T1WI, and 123 full-dose CE-BRAVO sequence-enhanced lesions were classified
as metastases. When metastases were ring-enhanced or solid-enhanced with a diameter
of <5 mm, the number of metastases detected in ½-dose CE-T2-FLAIR was higher
than that in ½-dose CE-T1WI and full-dose CE-BRAVO. However, if solid-enhanced
metastases were ≥5 mm, the number of
metastases detected in ½-dose CE-T2-FLAIR was less than that in ½-dose CE-T1WI or
full-dose CE-BRAVO. In 77 metastatic lesions which both displayed in three
sequences, the median CR was significantly higher using optimized ½-dose CE-T2-FLAIR
(in phase 2, CR=71.6) than ½-dose CE-T1WI (CR=11.7, P<0.001) or full-dose
CE-BRAVO sequence (CR=18.9, P<0.001). Conclusion
Conclusion: Half dose CE-T2-FLAIR has distinct advantage in detecting
brain metastases, especially ring-enhanced or small solid-enhanced lesions.
Acknowledgements
Bracco international B.V.
GE healthcare
References